4 completed, 1 terminated. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow ALLN-177: new trials by email Literature Review of ALLN-177 trials Research Report on ALLN-177
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria Reloxaliase, Placebo - Enteric Hyperoxaluria | Phase 3 | Terminated | Allena Pharmaceuticals | 92 | 2019-08-26 | 2022-06-10 |
| Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia ALLN-177 - Enteric Hyperoxaluria, Primary Hyperoxaluria | Phase 2 | Completed | Allena Pharmaceuticals | 15 | 2018-07-17 | 2020-12-30 |
| Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria ALLN-177, Placebo - Enteric Hyperoxaluria | Phase 3 | Completed | Allena Pharmaceuticals | 115 | 2018-05-21 | 2020-02-27 |
| Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days ALLN-177, Placebo - Secondary Hyperoxaluria, Nephrolithiasis | Phase 2 | Completed | Allena Pharmaceuticals | 66 | 2015-09-01 | 2017-01-19 |
| Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria ALLN-177 - Hyperoxaluria, Nephrolithiasis | Phase 2 | Completed | Allena Pharmaceuticals | 16 | 2014-09-01 | 2019-06-05 |
Kidney Calculi (5) · Hyperoxaluria (4) · Kidney Diseases (2) · Nephrolithiasis (2) · Urologic Diseases (2) · Hyperoxaluria, Primary (1)
United States (5) · Germany (3) · United Kingdom (3) · Canada (2) · France (2) · Italy (2) · Spain (2) · Austria (1) · Belgium (1) · Brazil (1) · Croatia (1) · Mexico (1) · Portugal (1) · Romania (1) · Russia (1)
Annamaria Kausz, MD MS (2) · David Clark, MD (2) · Lee Brettman, MD, FACP (1)
2017 (1), 2018 (1)